MX2021000083A - Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. - Google Patents
Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.Info
- Publication number
- MX2021000083A MX2021000083A MX2021000083A MX2021000083A MX2021000083A MX 2021000083 A MX2021000083 A MX 2021000083A MX 2021000083 A MX2021000083 A MX 2021000083A MX 2021000083 A MX2021000083 A MX 2021000083A MX 2021000083 A MX2021000083 A MX 2021000083A
- Authority
- MX
- Mexico
- Prior art keywords
- molecules
- cells
- treatment
- autoimmune diseases
- selectively activate
- Prior art date
Links
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 230000003213 activating effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Esta invención proporciona una proteína de fusión entre una proteína del agonista selectivo IL2aß? (agonista selectivo IL2) y una proteína Fc de IgG. La porción del agonista selectivo IL2 proporciona una actividad terapéutica para activar selectivamente la forma IL2aß? del receptor, estimulando selectivamente de esta forma las Treg. La porción Fc proporciona una vida media en circulación prolongada en comparación con la vida media en circulación de la proteína IL-2 o una IL2SA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461999241P | 2014-07-21 | 2014-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000083A true MX2021000083A (es) | 2021-03-25 |
Family
ID=55163946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000821A MX378790B (es) | 2014-07-21 | 2015-07-20 | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. |
| MX2021000083A MX2021000083A (es) | 2014-07-21 | 2017-01-18 | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000821A MX378790B (es) | 2014-07-21 | 2015-07-20 | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US20170037102A1 (es) |
| EP (2) | EP3587444A1 (es) |
| JP (2) | JP6768633B2 (es) |
| KR (1) | KR102493543B1 (es) |
| CN (2) | CN106795213B (es) |
| AU (3) | AU2015292889C1 (es) |
| CA (1) | CA2954847A1 (es) |
| DK (1) | DK3172227T3 (es) |
| EA (2) | EA038361B1 (es) |
| ES (1) | ES2763198T3 (es) |
| GB (1) | GB2538666A (es) |
| HU (1) | HUE046065T2 (es) |
| IL (3) | IL289475B2 (es) |
| LT (1) | LT3172227T (es) |
| MX (2) | MX378790B (es) |
| PL (1) | PL3172227T3 (es) |
| PT (1) | PT3172227T (es) |
| RS (1) | RS59789B1 (es) |
| SG (2) | SG11201700514SA (es) |
| SI (1) | SI3172227T1 (es) |
| WO (1) | WO2016014428A2 (es) |
| ZA (1) | ZA201700344B (es) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3640375A3 (en) | 2012-12-11 | 2020-07-29 | Albert Einstein College of Medicine | Methods for high throughput receptor/ligand identification |
| MX378790B (es) * | 2014-07-21 | 2025-03-10 | Delinia Inc | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. |
| EP3482766B1 (en) | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| IL283764B2 (en) | 2015-04-10 | 2024-01-01 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CN109071623B (zh) * | 2016-05-04 | 2022-05-27 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| KR20190019068A (ko) | 2016-05-18 | 2019-02-26 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| AU2017266905B2 (en) | 2016-05-18 | 2022-12-15 | Albert Einstein College Of Medicine, Inc. | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
| WO2018089420A1 (en) * | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
| CN110177564A (zh) * | 2016-12-13 | 2019-08-27 | 德里尼亚公司 | 多价的调节t细胞调节剂 |
| WO2018119114A1 (en) | 2016-12-22 | 2018-06-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3565829A4 (en) | 2017-01-09 | 2021-01-27 | Cue Biopharma, Inc. | T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| WO2018170168A1 (en) | 2017-03-15 | 2018-09-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| JP7001285B2 (ja) * | 2017-03-29 | 2022-01-19 | 国立大学法人 宮崎大学 | 長時間作用型アドレノメデュリン誘導体 |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| PH12020550661A1 (en) | 2017-11-21 | 2021-04-19 | Univ Leland Stanford Junior | Partial agonists of interleukin-2 |
| KR102684426B1 (ko) * | 2017-12-06 | 2024-07-11 | 팬디온 오퍼레이션스, 인코포레이티드 | Il-2 뮤테인 및 그 용도 |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| JP7765181B2 (ja) | 2017-12-19 | 2025-11-06 | ゼンコア インコーポレイテッド | 改変されたｉｌ－２ ｆｃ融合タンパク質 |
| WO2019131964A1 (ja) | 2017-12-27 | 2019-07-04 | 協和発酵キリン株式会社 | Ｉｌ－２改変体 |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| WO2019147837A2 (en) | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine fusion proteins |
| WO2019144309A1 (en) * | 2018-01-24 | 2019-08-01 | Beijing Percans Oncology Co. Ltd. | Cytokine Fusion Proteins |
| EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| TWI853807B (zh) | 2018-03-28 | 2024-09-01 | 美商必治妥美雅史谷比公司 | 介白素-2/介白素-2受體阿法融合蛋白及其使用方法 |
| EP3552738B1 (en) * | 2018-04-12 | 2024-07-31 | Sandvik Machining Solutions AB | A method of producing an additive manufactured object |
| CN120349426A (zh) | 2018-06-22 | 2025-07-22 | 科优基因公司 | 白介素-2变体及其使用方法 |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| CN112534052B (zh) | 2018-07-25 | 2024-09-20 | 奥美药业有限公司 | 全新il-21前药及使用方法 |
| EP3833679A1 (en) | 2018-08-06 | 2021-06-16 | Medikine, Inc. | Il-2 receptor binding compounds |
| ES3030707T3 (en) | 2018-08-13 | 2025-07-01 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| US20220056094A1 (en) * | 2018-12-21 | 2022-02-24 | Jiangsu Hengrui Medicine Co., Ltd. | Human interleukin-2 variant or derivative thereof |
| CN120157765A (zh) | 2019-02-01 | 2025-06-17 | 瑞泽恩制药公司 | 抗IL2受体γ抗原结合蛋白 |
| JP7570338B2 (ja) | 2019-02-15 | 2024-10-21 | インテグラル・モレキュラー・インコーポレイテッド | クローディン６抗体及びその使用 |
| JP2022520632A (ja) | 2019-02-15 | 2022-03-31 | インテグラル・モレキュラー・インコーポレイテッド | 共通軽鎖を含む抗体及びその使用 |
| CN114679909A (zh) | 2019-05-20 | 2022-06-28 | 潘迪恩运营公司 | MAdCAM靶向的免疫耐受 |
| US11845801B2 (en) | 2019-06-12 | 2023-12-19 | AskGene Pharma, Inc. | IL-15 prodrugs and methods of use thereof |
| EP4004025A1 (en) | 2019-07-26 | 2022-06-01 | Visterra, Inc. | Interleukin-2 agents and uses thereof |
| WO2021030483A1 (en) * | 2019-08-12 | 2021-02-18 | AskGene Pharma, Inc. | Il-2 fusion proteins that preferentially bind il-2ralpha |
| JP7427286B2 (ja) | 2019-11-05 | 2024-02-05 | メディカイン、インコーポレイテッド | ＩＬ－２ＲβγＣ結合化合物 |
| MX2022005404A (es) | 2019-11-05 | 2022-09-09 | Medikine Inc | Compuestos de fijación a il-2r e il-7r dual. |
| CA3159468A1 (en) * | 2019-12-12 | 2021-06-17 | David Klatzmann | Interleukin 2 chimeric constructs |
| US12091440B2 (en) | 2019-12-20 | 2024-09-17 | Regeneron Pharmaceuticals, Inc. | IL2 and peptide-MHC complex fusion proteins and methods of use thereof |
| CN115362168A (zh) | 2020-01-14 | 2022-11-18 | 辛德凯因股份有限公司 | 偏向化il2突变蛋白方法和组合物 |
| MX2022009390A (es) | 2020-02-03 | 2022-11-16 | Medikine Inc | Compuestos de unión a il-7r¿¿c. |
| WO2021158619A1 (en) | 2020-02-03 | 2021-08-12 | Medikine, Inc. | IL-7Rα BINDING COMPOUNDS |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| US11028132B1 (en) | 2020-04-07 | 2021-06-08 | Yitzhak Rosen | Half-life optimized linker composition |
| CN116096405A (zh) | 2020-05-12 | 2023-05-09 | Cue生物制药股份有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| GB2621482B (en) | 2020-05-13 | 2024-09-04 | Bonum Therapeutics Inc | Compositions of protein complexes and methods of use thereof |
| KR20230060514A (ko) * | 2020-09-01 | 2023-05-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 인터루킨-2 뮤테인 및 이의 용도 |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| WO2022087458A1 (en) | 2020-10-23 | 2022-04-28 | Asher Biotherapeutics, Inc. | Fusions with cd8 antigen binding molecules for modulating immune cell function |
| CA3195260A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| JP2023549191A (ja) | 2020-11-13 | 2023-11-22 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ヒトインターロイキン２の変異体又はその誘導体を含む医薬組成物及びその用途 |
| CA3203977A1 (en) | 2020-12-04 | 2022-06-09 | Visterra, Inc. | Methods of using interleukin-2 agents |
| IL304365B2 (en) * | 2021-03-31 | 2025-04-01 | Hanmi Pharmaceutical Co Ltd | A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof |
| BR112023020597A2 (pt) | 2021-04-09 | 2023-12-12 | Selecta Biosciences Inc | Nanocarreadores sintéticos que compreendem um imunossupressante em combinação com agonistas do receptor de il-2 de alta afinidade para aumentar a tolerância imune |
| KR20240113459A (ko) | 2021-10-06 | 2024-07-22 | 일투 파마 | 염증 조직에 대한 표적화 특이성을 갖는 인터루킨 2 키메라 구성체 |
| US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| US20250082777A1 (en) | 2022-01-10 | 2025-03-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023172628A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| WO2023183568A1 (en) | 2022-03-25 | 2023-09-28 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| US20230381277A1 (en) | 2022-04-08 | 2023-11-30 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| IL319435A (en) | 2022-09-12 | 2025-05-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Interleukin-2 for use in the treatment of autism spectrum disorder |
| KR20250114330A (ko) | 2022-11-30 | 2025-07-29 | 인테그럴 몰큘러 인코포레이티드 | 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식 |
| CN120529914A (zh) | 2023-01-09 | 2025-08-22 | 奥德赛治疗股份有限公司 | 抗tnfr2抗原结合蛋白及其用途 |
| WO2024229380A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases |
| WO2024229370A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Compositions and methods for treating gvhd |
| WO2024229350A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes |
| WO2024229432A1 (en) | 2023-05-03 | 2024-11-07 | Cartesian Therapeutics, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2026006809A1 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Multispecific molecules binding tnfr2 and cd25 and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| EP1421187B1 (en) | 2001-07-27 | 2007-10-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Systems for in vivo site-directed mutagenesis using oligonucleotides |
| PL206975B1 (pl) * | 2001-12-04 | 2010-10-29 | Merck Patent Gmbh | Immunocytokiny o modulowanej selektywności oraz ich zastosowanie |
| ATE525395T1 (de) | 2003-06-12 | 2011-10-15 | Lilly Co Eli | Fusions proteine von glp-1-analoga |
| ATE554108T1 (de) * | 2003-07-25 | 2012-05-15 | Amgen Inc | Verfahren bezüglich ldcam und crtam |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| JP2007527242A (ja) * | 2004-03-05 | 2007-09-27 | カイロン コーポレーション | 治療剤の患者耐容性を予測するためのインビトロ試験システム |
| AU2007271398B2 (en) * | 2006-07-06 | 2013-06-20 | Merck Patent Gmbh | Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses |
| AU2007305443B2 (en) * | 2006-09-29 | 2012-08-23 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| EP2382228B2 (en) * | 2009-01-21 | 2026-01-07 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| ES2572728T3 (es) * | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
| PL2542590T5 (pl) * | 2010-03-05 | 2020-08-10 | The Johns Hopkins University | Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych |
| CN102174111B (zh) * | 2011-01-25 | 2013-01-09 | 江苏省弗泰生物科技有限公司 | 人白介素2-Fc融合蛋白及其用途 |
| TWI666027B (zh) * | 2011-02-10 | 2019-07-21 | 羅齊克雷雅公司 | 突變介白素-２多肽 |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| JP2014094898A (ja) * | 2012-11-07 | 2014-05-22 | Univ Of Tsukuba | 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用 |
| US9546203B2 (en) * | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| EP3421495A3 (en) * | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| CN103193887B (zh) * | 2013-04-03 | 2015-02-04 | 江苏众红生物工程创药研究院有限公司 | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 |
| MX378790B (es) * | 2014-07-21 | 2025-03-10 | Delinia Inc | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. |
| US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
-
2015
- 2015-07-20 MX MX2017000821A patent/MX378790B/es unknown
- 2015-07-20 AU AU2015292889A patent/AU2015292889C1/en not_active Withdrawn - After Issue
- 2015-07-20 SG SG11201700514SA patent/SG11201700514SA/en unknown
- 2015-07-20 SG SG10202010158TA patent/SG10202010158TA/en unknown
- 2015-07-20 ES ES15824955T patent/ES2763198T3/es active Active
- 2015-07-20 SI SI201530968T patent/SI3172227T1/sl unknown
- 2015-07-20 EA EA201790213A patent/EA038361B1/ru unknown
- 2015-07-20 KR KR1020177001922A patent/KR102493543B1/ko active Active
- 2015-07-20 HU HUE15824955A patent/HUE046065T2/hu unknown
- 2015-07-20 CA CA2954847A patent/CA2954847A1/en active Pending
- 2015-07-20 IL IL289475A patent/IL289475B2/en unknown
- 2015-07-20 EP EP19188596.1A patent/EP3587444A1/en not_active Withdrawn
- 2015-07-20 EP EP15824955.7A patent/EP3172227B9/en active Active
- 2015-07-20 LT LTEP15824955.7T patent/LT3172227T/lt unknown
- 2015-07-20 PL PL15824955T patent/PL3172227T3/pl unknown
- 2015-07-20 EA EA202190903A patent/EA202190903A3/ru unknown
- 2015-07-20 GB GB1615553.3A patent/GB2538666A/en not_active Withdrawn
- 2015-07-20 PT PT158249557T patent/PT3172227T/pt unknown
- 2015-07-20 CN CN201580050979.6A patent/CN106795213B/zh not_active Expired - Fee Related
- 2015-07-20 JP JP2017504096A patent/JP6768633B2/ja not_active Expired - Fee Related
- 2015-07-20 DK DK15824955T patent/DK3172227T3/da active
- 2015-07-20 WO PCT/US2015/041177 patent/WO2016014428A2/en not_active Ceased
- 2015-07-20 RS RS20191448A patent/RS59789B1/sr unknown
- 2015-07-20 CN CN202111371055.XA patent/CN114133456A/zh active Pending
-
2016
- 2016-09-14 US US15/265,764 patent/US20170037102A1/en not_active Abandoned
- 2016-09-14 US US15/265,770 patent/US20170051029A1/en not_active Abandoned
-
2017
- 2017-01-10 IL IL250024A patent/IL250024B/en active IP Right Grant
- 2017-01-16 ZA ZA2017/00344A patent/ZA201700344B/en unknown
- 2017-01-18 MX MX2021000083A patent/MX2021000083A/es unknown
- 2017-07-28 US US15/662,633 patent/US20170327555A1/en not_active Abandoned
-
2019
- 2019-01-17 US US16/250,255 patent/US20190375812A1/en not_active Abandoned
-
2020
- 2020-04-07 US US16/841,815 patent/US20210047382A1/en not_active Abandoned
- 2020-05-27 AU AU2020203480A patent/AU2020203480A1/en not_active Abandoned
- 2020-09-02 JP JP2020147441A patent/JP2021006038A/ja active Pending
- 2020-10-26 IL IL278299A patent/IL278299B/en unknown
-
2021
- 2021-12-20 US US17/556,208 patent/US20220112260A1/en not_active Abandoned
-
2022
- 2022-07-11 AU AU2022204946A patent/AU2022204946A1/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000083A (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. | |
| MX2018008840A (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades. | |
| ZA201708000B (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| GB2564823A (en) | Compositions and methods for T-cell receptors reprogramming using fusion proteins | |
| MX2020004206A (es) | Variantes il-2 modificadas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunitarias. | |
| EA201991142A1 (ru) | Варианты il-2 для лечения аутоиммунных заболеваний | |
| MX390878B (es) | Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1). | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MY205850A (en) | Proteins binding bcma, nkg2d and cd16 | |
| MX2016010953A (es) | Proteinas de fc multimericas. | |
| EP4273258A3 (en) | Proteins binding her2, nkg2d and cd16 | |
| CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
| NZ737399A (en) | Ccr2 modulators | |
| MX2017006694A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
| MX2019009847A (es) | Proteínas que se unen a cd123, nkg2d y cd16. | |
| MX2019009541A (es) | Proteinas que se unen a psma, nkg2d y cd16. | |
| WO2018067520A3 (en) | Therapeutic agents and methods: | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
| MY206426A (en) | Anti-cd38 antibodies and formulations | |
| MX370897B (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades, | |
| EA201890148A1 (ru) | Способ индукции раннего ответа т-клеток памяти противоопухолевой вакциной из коротких пептидов | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. | |
| EA201990824A1 (ru) | Антитела, которые связываются с интерлейкином-2, и их применение |